The Spanish Lung Cancer Group (GECP) highlights new biomarker and environmental findings in lung cancer at ESMO 2026:
” ‘Post-surgical Molecular Residual Disease and Pathological Complete Response after Perioperative Nivolumab in Resectable Stage III NSCLC: Exploratory Analysis from NADIM II‘.
The study, led by Pilar Mediavilla, with the participation of Virginia Calvo and M.Provencio, explores molecular residual disease after surgery and its relationship with pathological complete response in patients treated with perioperative nivolumab.
‘Impact of Residential Radon Exposure on the Molecular Profile of Lung Cancer in Spain: Results from the RTT-ATLAS-Radon Study.’
The research, led by Virginia Calvo and featuring the participation of Alberto Ruano, analyzes the relationship between residential radon exposure and the molecular characteristics of lung cancer in Spain.”
You can also read:
25 Posts Not to Miss from ESMO Congress 2026: Day 4
